Pseudonymization of patient identifiers for translational research

The invention presents a new method for pseudonymizing e.g. patient identifiers in which the pseudonymmization service provider is unable to derive the patient identifier from the pseudonym, but rather this ability is assigned to an authorized third party (Ombudsman). This is achieved by asymmetric and symmetric encryption algorithms and key derivation functions in combination with a new algorithm to pseudonymize a patient identifier. The asymmetric and symmetric encryption algorithms used in the pseudonymization software are approved by the technical directive TR-03116 for eCard-Projects of the German Federal Government. The method/software can be used for pseudonymmization of any sensitive data if they are processed by third-party institutions e.g. patient samples for translational research or bank account data.

Further information: PDF

DKFZ (German Cancer Research Center, Deutsches Krebsforschungszentrum)
Phone: +49-6221-42 2955

Contact
Dr. Ruth Herzog

As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

After 25 years, researchers uncover genetic cause of rare neurological disease

Some families call it a trial of faith. Others just call it a curse. The progressive neurological disease known as spinocerebellar ataxia 4 (SCA4) is a rare condition, but its…

Lower dose of mpox vaccine is safe

… and generates six-week antibody response equivalent to standard regimen. Study highlights need for defined markers of mpox immunity to inform public health use. A dose-sparing intradermal mpox vaccination regimen…

Efficient, sustainable and cost-effective hybrid energy storage system for modern power grids

EU project HyFlow: Over three years of research, the consortium of the EU project HyFlow has successfully developed a highly efficient, sustainable, and cost-effective hybrid energy storage system (HESS) that…

Partners & Sponsors